Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has launched a pro-rata non-renounceable entitlement offer to raise up to approximately $17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an issue price of $0.08 per share, based on a record date of 30 December 2025. The offer will be conducted without a prospectus under Australia’s cleansing notice provisions, with the company confirming compliance with continuous disclosure obligations and stating that, given the pro-rata structure and current substantial holdings, the capital raising is not expected to have any material impact on the control of the company, thereby providing additional funding with limited governance disruption for existing investors.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate patient access to effective ALS therapies while exploring broader neurodegenerative indications through international collaborations and clinical programs.
Average Trading Volume: 817,788
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.